CA2222550A1 - Transporteurs d'acide nucleique servant a introduire des acides nucleiques dans une cellule - Google Patents

Transporteurs d'acide nucleique servant a introduire des acides nucleiques dans une cellule Download PDF

Info

Publication number
CA2222550A1
CA2222550A1 CA002222550A CA2222550A CA2222550A1 CA 2222550 A1 CA2222550 A1 CA 2222550A1 CA 002222550 A CA002222550 A CA 002222550A CA 2222550 A CA2222550 A CA 2222550A CA 2222550 A1 CA2222550 A1 CA 2222550A1
Authority
CA
Canada
Prior art keywords
nucleic acid
jts
cell
dna
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002222550A
Other languages
English (en)
Inventor
James T. Sparrow
Louis C. Smith
Savio L.C. Woo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2222550A1 publication Critical patent/CA2222550A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention porte sur des systèmes de transport d'acide nucléique servant à apporter de l'acide nucléique à une cellule. Ce transporteur d'acide nucléique comporte un complexe de liaison qui contient une molécule de liaison se liant de manière non covalente à l'acide nucléique. Le complexe de liaison peut également contenir une molécule de liaison associée à un ligand de surface, un ligand de noyau ou un agent de lyse. Ces derniers peuvent être associés à la molécule de liaison au moyen d'une séquence intercalaire. Le transporteur peut comporter, de surcroît, un acide nucléique avec une combinaison des complexes de liaison ou molécules de liaison susmentionnés.
CA002222550A 1995-06-07 1996-04-23 Transporteurs d'acide nucleique servant a introduire des acides nucleiques dans une cellule Abandoned CA2222550A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48477795A 1995-06-07 1995-06-07
US08/484,777 1995-06-07

Publications (1)

Publication Number Publication Date
CA2222550A1 true CA2222550A1 (fr) 1996-12-19

Family

ID=23925558

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002222550A Abandoned CA2222550A1 (fr) 1995-06-07 1996-04-23 Transporteurs d'acide nucleique servant a introduire des acides nucleiques dans une cellule

Country Status (5)

Country Link
EP (1) EP0832269A1 (fr)
JP (1) JPH11506722A (fr)
AU (1) AU705035B2 (fr)
CA (1) CA2222550A1 (fr)
WO (1) WO1996040958A1 (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6344436B1 (en) * 1996-01-08 2002-02-05 Baylor College Of Medicine Lipophilic peptides for macromolecule delivery
WO1998050078A1 (fr) * 1997-05-02 1998-11-12 Genemedicine, Inc. Peptides lipophiles et/ou lytiques permettant l'apport specifique d'acides nucleiques a des cellules
EP1007099A4 (fr) 1997-07-11 2004-11-24 Univ Brandeis Procede pour induire l'apoptose par la reduction du taux de thiamine
WO1999012945A2 (fr) * 1997-09-08 1999-03-18 Valentis,Inc. Derives de glycosylamine hydrophobes, compositions a base de ces derives et procedes d'utilisation
AU9667798A (en) * 1997-09-26 1999-04-12 University Of Connecticut, The Multicomponent polynucleotide complex for high efficiency cell transfection
CA2315256A1 (fr) * 1997-12-16 1999-06-24 Valentis, Inc. Injection sans aiguille de molecules d'acide nucleique formules
CA2317549C (fr) * 1998-01-05 2006-04-11 University Of Washington Composition pour l'amelioration du transport par l'utilisation de membranes contenant des lipides et utilisation connexe
US6372720B1 (en) * 1998-02-05 2002-04-16 Kenneth J. Longmuir Liposome fusion and delivery vehicle
US5973119A (en) 1998-06-05 1999-10-26 Amgen Inc. Cyclin E genes and proteins
DE19829005C2 (de) * 1998-06-29 2000-08-31 November Ag Molekulare Medizin Verfahren zum Transport molekularer Substanz in vorgegebene Bereiche eukaryontischer Zellen
US6344541B1 (en) 1998-09-25 2002-02-05 Amgen Inc. DKR polypeptides
US6903077B1 (en) * 1999-01-04 2005-06-07 University Of Vermont And State Agricultural College Methods and products for delivering nucleic acids
NZ551331A (en) 1999-02-03 2008-08-29 Amgen Inc Methods using polypeptides involved in immune response
US8624010B1 (en) 1999-02-03 2014-01-07 Steven K. Yoshinaga Nucleic acids encoding B7RP1
US7708993B2 (en) 1999-02-03 2010-05-04 Amgen Inc. Polypeptides involved in immune response
US7435796B1 (en) 1999-02-03 2008-10-14 Amgen Inc. Antibodies which bind B7RP1
WO2000058479A1 (fr) 1999-03-26 2000-10-05 Amgen Inc. Genes et polypeptides beta secretase
WO2000063409A1 (fr) * 1999-04-21 2000-10-26 Massachusetts Institute Of Technology Agents endosomolytiques et systemes de liberation dans des cellules
EP1052288A1 (fr) * 1999-05-10 2000-11-15 Transgene S.A. Complexe pour le transfert d'une substance anionique dans une cellule
EP1052287A3 (fr) * 1999-05-10 2003-07-09 Transgene S.A. Complexe pour le transfert d'une substance anionique d'intérêt dans une cellule
FR2797402B1 (fr) 1999-07-15 2004-03-12 Biomerieux Stelhys Utilisation d'un polypeptide pour detecter, prevenir ou traiter un etat pathologique associe a une maladie degenerative, neurologique ou autoimmune
US7408047B1 (en) 1999-09-07 2008-08-05 Amgen Inc. Fibroblast growth factor-like polypeptides
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US6900043B1 (en) 1999-09-21 2005-05-31 Amgen Inc. Phosphatases which activate map kinase pathways
AU2764801A (en) 2000-01-07 2001-07-24 University Of Washington Enhanced transport of agents using membrane disruptive agents
US7514239B2 (en) 2000-03-28 2009-04-07 Amgen Inc. Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
AU2000239309A1 (en) * 2000-03-29 2001-10-08 Dgi Biotechnologies Llc Insulin and igf-1 receptor agonists and antagonists
EP1161957A1 (fr) * 2000-05-26 2001-12-12 Transgene S.A. Complexe pour le transfert d'une substance anionique d' intérêt dans une cellule
CA2413596A1 (fr) * 2000-06-28 2002-01-03 Joyce Driscoll Lignees cellulaires et dosages a base de cellules permettant d'identifier des modulateurs de recepteurs d'androgenes
JP2004519205A (ja) 2000-06-28 2004-07-02 アムジェン インコーポレイテッド 胸腺間質リンホポイエチンレセプター分子およびその使用
EP1170373A1 (fr) * 2000-07-03 2002-01-09 Retina France Transfection des cellules de l'oeil médiée par des peptides
EP1337634A2 (fr) 2000-11-28 2003-08-27 Amgen Inc. Nouveaux polypeptides impliques dans la reponse immunitaire
JP2004534004A (ja) * 2001-02-27 2004-11-11 トランジェーヌ、ソシエテ、アノニム ポリヌクレオチドを細胞へトランスフェクションするための組成物を製造するための非複合体化ペプチドの使用および遺伝子治療において有用な組成物
US7662924B2 (en) 2002-02-22 2010-02-16 The Board Of Trustees Of The University Of Illinois Beta chain-associated regulator of apoptosis
CA2531773A1 (fr) 2003-07-21 2005-02-17 Transgene S.A. Nouvelles cytokines multifonctionnelles
EP1758999B1 (fr) 2004-06-22 2011-03-09 The Board Of Trustees Of The University Of Illinois Procedes pour inhiber la proliferation des cellules tumorales avec foxm1 arnsi
CA2592292A1 (fr) * 2005-01-04 2006-07-13 The Brigham And Women's Hospital, Inc. Liberation prolongee de pdgf au moyen de nanofibres de peptides autoassembles
US7906484B2 (en) * 2006-09-21 2011-03-15 Alnylam Pharmaceuticals, Inc. Complex for transferring an anionic substance into a cell
US8282918B2 (en) 2007-07-30 2012-10-09 University Of Iowa Research Foundation Polynucleotides encoding RPA4/RPA32 hybrid polypeptides
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
WO2010020798A2 (fr) * 2008-08-21 2010-02-25 King's College London Nanoparticules
MX341149B (es) 2008-10-10 2016-08-09 Amgen Inc Mutantes fgf21 y uso de los mismos.
CA2760674A1 (fr) 2009-05-05 2010-11-11 Amgen Inc. Mutants de fgf21 et leurs utilisations
PE20120358A1 (es) 2009-05-05 2012-04-26 Amgen Inc Mutantes fgf21 y usos de los mismos
AU2010316996A1 (en) 2009-11-05 2012-06-14 Proyecto De Biomedicina Cima, S.L. Regulated expression systems
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
MX2012011986A (es) 2010-04-15 2013-03-05 Amgen Inc RECEPTOR FGF HUMANO Y PROTEINAS ENLAZADAS A ß-KLOTHO.
US9273316B2 (en) 2010-05-21 2016-03-01 Peptimed, Inc. Reagents and methods for treating cancer
WO2012095548A2 (fr) 2011-01-13 2012-07-19 Centro De Investigación Biomédica En Red De Enfermedades Neurodegenerativas (Ciberned) Composés pour le traitement de maladies neurodégénératives
CN104870477B (zh) 2012-10-23 2018-10-09 爱默蕾大学 Gm-csf和il-4轭合物、组合物以及与其相关的方法
JOP20140087B1 (ar) 2013-03-13 2021-08-17 Amgen Inc بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
WO2017205846A1 (fr) 2016-05-27 2017-11-30 Aadigen, Llc Peptides et nanoparticules pour l'administration intracellulaire de molécules d'édition du génome
US10183058B2 (en) 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
US10172910B2 (en) 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
US10532081B2 (en) 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
EP3793595A1 (fr) 2018-05-15 2021-03-24 Immunomic Therapeutics, Inc. Constructions améliorées de lamp comprenant des allergènes
WO2020097235A1 (fr) * 2018-11-08 2020-05-14 Summation Bio, Inc. Proétéines de noyau de mini-nucléosomes et leur utilisation dans l'administration d'acides nucléiques

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135736A (en) * 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
CA2131620A1 (fr) * 1992-03-20 1993-09-30 Louis C. Smith Systeme de transport de l'adn et mode d'emploi
EP0693939A1 (fr) * 1993-04-14 1996-01-31 Roche Diagnostics GmbH Peptides de tranfert d'acides nucleiques et leur utilisation pour injecter des acides nucleiques dans des cellules eucaryotes

Also Published As

Publication number Publication date
AU705035B2 (en) 1999-05-13
JPH11506722A (ja) 1999-06-15
WO1996040958A1 (fr) 1996-12-19
EP0832269A1 (fr) 1998-04-01
AU5714296A (en) 1996-12-30

Similar Documents

Publication Publication Date Title
AU705035B2 (en) Nucleic acid transporters for delivery of nucleic acids into a cell
AU722700B2 (en) Lipophilic peptides for macromolecule delivery
Martin et al. Peptide-guided gene delivery
Pichon et al. Histidine-rich peptides and polymers for nucleic acids delivery
US6177554B1 (en) Nucleic acid transporter systems
Garnett Gene-delivery systems using cationic polymers
JPH10506001A (ja) 核酸複合体を高等真核生物の細胞に導入するための組成物
JP4293292B2 (ja) トランスフェクション活性を有するインテグリン−ターゲッティングベクター
US20030165567A1 (en) Histidine copolymer and methods for using same
US7442764B2 (en) Reversible modification of amine-containing compounds
US7019113B2 (en) Reversible modification of membrane interaction
JP2002514892A (ja) 遺伝子治療における合成ウイルス様粒子の使用
JPH11506935A (ja) ペプチド増強カチオン脂質トランスフェクション
US7741431B2 (en) Liposomes containing novel targeting and/or fusogenic peptides, preparations containing them and therapeutic use thereof
KR19980702200A (ko) 핵산 함유 조성물과 이의 제조방법 및 용도
Liu et al. Macro-branched cell-penetrating peptide design for gene delivery
JP7333635B2 (ja) ｍＲＮＡを細胞に送達するための改善した脂質－ペプチドナノ複合体製剤
CA2325744A1 (fr) Fusion de liposome et vehicule d'administration
JP2003530360A (ja) 薬剤送達のためのペプチド複合体
AU749113B2 (en) Compositions and methods for highly efficient transfection
JP2000506388A (ja) 近共通スプライス部位を有する無イントロン遺伝子の発現を増大させるためのウイルスのシス作用性転写後調節配列の用途
CA2481399A1 (fr) Peptides, compositions pharmaceutiques contenant ces peptides pour le traitement du cancer
WO1998050078A1 (fr) Peptides lipophiles et/ou lytiques permettant l'apport specifique d'acides nucleiques a des cellules
US6479464B1 (en) Compositions and methods for highly efficient transfection
Peluffo Modular multifunctional protein vectors for gene therapy

Legal Events

Date Code Title Description
FZDE Dead